Jan Krejsek

Jan Krejsek

Auto-generated profile, based on publicly available information

Jan Krejsek

Department of Clinical Immunology and Allergy, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2012 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
PKP. Kunes
P. Kunes
ZHZ. Holubcova
Z. Holubcova
MKMartina Kolackova
Martina Kolackova
JKJ. Krejsek
J. Krejsek
Inflammatory or anti-inflammatory? That is the question as far as the acute-phase response and its mediators, the pentraxins, are concerned. Only some ten years ago, the classical or short pentraxin C-reactive protein and the newly discovered long pentraxin PTX3 were considered to exert most of the detrimental effects of acute inflammation, whether microbial or sterile in origin. However, accumulating evidence suggests an at least dichotomous, context-dependent outcome attributable to the pentraxins, if not a straightforward anti-inflammatory nature of the acute-phase response. This paper is focused on the inherent effects of pentraxin 3 in inflammatory responses, mainly in coronary artery disease and inAspergillus fumigatusinfection. Both are examples of inflammatory reactions in which PTX3 is substantially involved; the former sterile, the latter infectious in origin. Apart from different inducing noxae, similarities in the pathogenesis of the two are striking. All the same, the introductory question still persists: is the ultimate impact of PTX3 in these conditions inflammatory or anti-inflammatory, paradoxical as the latter might appear? We try to provide an answer such as it emerges in the light of recent findings.

1 January 2009 in Acta Medica (Hradec Kralove, Czech Republic)
Verified
Journal Article
Open access
PDF file
GOGabriela Onofre
Gabriela Onofre
MKMartina Koláčková
Martina Koláčková
KJKarolína Jankovičová
Karolína Jankovičová
JKJan Krejsek
Jan Krejsek
CD163 is a member of scavenger receptor super family class B of the first subgroup. It is mapped to the region p13 on chromosome 12. Five different isoforms of CD163 have been described, which differ in the structure of their cytoplasmic domains and putative phosporylation sites. This scavenger receptor is selectively expressed on cells of monocytes and macrophages lineage exclusively. CD163 immunological function is essentially homeostatic. It also has other functions because participates in adhesion to endothelial cells, in tolerance induction and tissues regeneration. Other very important function of CD163 is the clearance of hemoglobin in its cell-free form and participation in anti-inflammation in its soluble form, exhibiting cytokine-like functions. We review the biological functions of CD163 which have been discovered until now. It seems apparent from this review that CD163 scavenger receptor can be used as biomarker in different diseases and as a valuable diagnostic parameter for prognosis of many diseases especially inflammatory disorders and sepsis.

1 January 2012 in Acta Medica (Hradec Kralove, Czech Republic)
Verified
Journal Article
Open access
PDF file
DHDrahomíra Holmannová
Drahomíra Holmannová
MKMartina Koláčková
Martina Koláčková
KKKateřIna Kondělková
KateřIna Kondělková
PKPavel Kuneš
Pavel Kuneš
JKJan Krejsek
Jan Krejsek
CACtirad Andrýs
Ctirad Andrýs
CD200/CD200R are highly conserved type I paired membrane glycoproteins that belong to the Ig superfamily containing a two immunoglobulin‑like domain (V, C). CD200 is broadly distributed in a variety of cell types, whereas CD200R is primarily expressed in myeloid and lymphoid cells. They fulfill multiple functions in regulating inflammation. The interaction between CD200/CD200R results in activation of the intracellular inhibitory pathway with RasGAP recruitment and thus contributes to effector cell inhibition. It was confirmed that the CD200R activation stimulates the differentiation of T cells to the Treg subset, upregulates indoleamine 2,3‑dioxygenase activity, modulates cytokine environment from a Th1 to a Th2 pattern, and facilitates an antiinflammatory IL‑10 and TGF‑β synthesis. CD200/CD200R are required for maintaining self‑tolerance. Many studies have demonstrated the importance of CD200 in controlling autoimmunity, inflammation, the development and spread of cancer, hypersensitivity, and spontaneous fetal loss.

1 January 2007 in Scandinavian Cardiovascular Journal
Verified
Journal Article
Closed access
PKPavel Kunes
Pavel Kunes
VLVladimir Lonsky
Vladimir Lonsky
JMJiri Mandak
Jiri Mandak
MKMartina Kolackova
Martina Kolackova
CACtirad Andrys
Ctirad Andrys
JKJan Krejsek
Jan Krejsek
Objective. Pentraxin 3 (PTX3) is a newly identified acute phase reactant with non-redundant functions in innate immunity. The purpose of this study was to assess the kinetics of release of PTX3 in cardiac surgical patients, operated on either with or without the use of cardiopulmonary bypass (CPB). Design. Thirty-four patients, seventeen in each group, were randomly assigned to CABG surgery performed either with (“on-pump”) or without (“off-pump”) CPB. Blood samples were collected both during and after the operation up to the 7th day. Results. In patients operated on with the use of CPB, PTX3 levels increased throughout the operation. Compared to baseline levels the highest PTX3 value (p<0.000) was attained on the 1st postoperative day in both “on-pump” and “off-pump” patients. In contrast to CPB patients, however, PTX3 levels in the latter group declined slowly, remaining elevated as long as the 3rd postoperative day (p<0.042). Conclusions. Operations performed with the use of CPB are associated with a more pronounced release of PTX3 immediatelly after operation.

1 January 2008 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MKMartina Kolackova
Martina Kolackova
MKManuela Kudlova
Manuela Kudlova
PKPavel Kunes
Pavel Kunes
VLVladimir Lonsky
Vladimir Lonsky
JMJiri Mandak
Jiri Mandak
JKJan Krejsek
Jan Krejsek
Objective. Activation of innate immunity cells is inseparably linked to cardiac surgical operation. The aim of this study was to assess the kinetics in the expression of receptor for Fc part of IgG, FcγRI (CD64), and scavenger receptor CD163 on peripheral blood cells of cardiac surgical patients and to examine the effect of cardiac bypass as a separable influence on the systemic acute inflammatory response. Methods. Forty patients, twenty in each group, were randomly assigned to CABG surgery performed either with “on‐pump” or without “off‐pump” cardiopulmonary bypass. Standardized quantitative flow cytometry method was used to determine the expression of surface markers. Results. The density of CD64 molecule on monocytes reached maximum on the 1st postoperative day (P < .001) whereas the peak for CD64 molecule expression on granulocytes was postponed to the 3rd postoperative day (P < .001). The expression of CD163 scavenger molecule on monocytes reached maximum on the 1st postoperative day (P < .001). The density of CD163 molecule on monocytes on the 1st postoperative day is significantly higher in “on‐pump” patients in comparison with “off‐pump” patients (P < .001). Conclusion. In cardiac surgical patients the expression of activation marker FcγR1 (CD64) on monocytes is increased earlier in comparison with granulocytes in both “on‐pump” and “off‐pump” patients. The expression of scavenger molecule CD163 on monocytes is significantly higher in “on‐pump” patients.

1 January 2012 in Acta Medica (Hradec Kralove, Czech Republic)
Verified
Journal Article
Open access
PDF file
DHDrahomíra Holmannová
Drahomíra Holmannová
MKMartina Koláčková
Martina Koláčková
KKKateřIna Kondělková
KateřIna Kondělková
PKPavel Kuneš
Pavel Kuneš
JKJan Krejsek
Jan Krejsek
CACtirad Andrýs
Ctirad Andrýs
CD200 and its receptor were recognized as having the multiple immunoregulatory functions. Their immunoregulatory, suppressive, and tolerogenic potentials could be very effectively exploited in the treatment of many diseases, e.g. Alzheimer disease, rheumatoid arthritis, and allergy to name only some. Many research projects are aimed to develop clinically valuable methods being based on the structure and function of these paired molecules. In this review, we would like to introduce CD200/CD200R functions in a clinical context.